echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Xikang cooperates with afinita biotech to develop new anti-cancer monoclonal antibody drugs

    Xikang cooperates with afinita biotech to develop new anti-cancer monoclonal antibody drugs

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Xikang (Cayman) Holding Co., Ltd

    (Emerging Stock Code: 6540) announced that its subsidiary Xikang biotechnology signed a commissioned development and manufacturing contract with afinita biotech of the United States, and will cooperate to develop new anti-cancer monoclonal antibody drugs of afinita biotech

    JHL logo high resolution estimates that the total value of the contract will be nearly 20 million US dollars by 2020

    Xikang will provide cell line development, process development, mass production and other professional technologies for afinita biotech anti-cancer monoclonal antibody new drugs with its plant facilities in Zhubei, Taiwan and Wuhan, China

    About afinita biotechnology located in San Francisco, California, USA, founded in 2015 by a group of industry experts; afinita biotechnology focuses on the research and development of new anti-cancer drugs based on target therapy and immunotherapy

    About Xikang Xikang, founded by a group of senior people with rich R & D and production experience in the field of biotechnology, supported by several top-level venture capital, including Kleiner Perkins Caufield & Byers, Sequoia Capital, biomark capital, milestone capital, fidelity and China Development Industrial Bank, etc

    Hikvision's mission is to provide affordable world-class drugs for more patients around the world

    Xikang has built a world-class biopharmaceutical factory that meets the cGMP standards of the United States, the European Union and the International Coordination Conference (ICH) and local standards

    Xikang biological Taiwan R & D center supports the R & D work in preclinical and early clinical stages of similar biological drugs; Xikang biological Wuhan pharmaceutical factory will support the commercial production of biological drugs, which also enables Xikang biological to have a unique production capacity, enable it to produce its own products, and also provide contract processing services for specific customers

    For more information, please visit our website
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.